Publications by authors named "Fong Clow"

Claim this Profile
A
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Pablo C Okhuysen, Mayur S Ramesh, Thomas Louie, Nino Kiknadze, Julian Torre-Cisneros, Fong Clow

Clin Infect Dis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Edmund K Waller, David Miklos, Corey Cutler, Mukta Arora, Madan H Jagasia, Fong Clow

Biol Blood Marrow Transplant· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Jan A Burger, Mariela Sivina, Nitin Jain, Ekaterina Kim, Tapan Kadia, Fong Clow

Blood· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Fong Clow

Lancet Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Jeffrey Jones, Anthony Mato, Steven Coutre, John C Byrd, Richard R Furman, Fong Clow

Br J Haematol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Paul G Richardson, William I Bensinger, Carol Ann Huff, Caitlin L Costello, Nikoletta Lendvai, Fong Clow

Br J Haematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Simon Rule, Martin Dreyling, Andre Goy, Georg Hess, Rebecca Auer, Fong Clow

Br J Haematol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Jennifer R Brown, Javid Moslehi, Susan O'Brien, Paolo Ghia, Peter Hillmen, Fong Clow

Haematologica· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Christine E Ryan, Bita Sahaf, Aaron C Logan, Susan O'Brien, John C Byrd, Fong Clow

Blood· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Susan O'Brien, Jeffrey A Jones, Steven E Coutre, Anthony R Mato, Peter Hillmen, Fong Clow

Lancet Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Jan A Burger, Alessandra Tedeschi, Paul M Barr, Tadeusz Robak, Carolyn Owen, Fong Clow

N Engl J Med· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Urte Gayko, Mann Fung, Fong Clow, Steven Sun, Elizabeth Faust

Ann N Y Acad Sci· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, Fong Clow

Nat Med· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Jennifer R Brown, Jacqueline C Barrientos, Paul M Barr, Ian W Flinn, Jan A Burger, Fong Clow

Blood· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib in previously treated Waldenström's macroglobulinemia.
Steven P Treon, Christina K Tripsas, Kirsten Meid, Diane Warren, Gaurav Varma, Fong Clow

N Engl J Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.
David D Smith, Leanne Goldstein, Mei Cheng, Danelle F James, Lori A Kunkel, Fong Clow

Ann Hematol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C Byrd, Jennifer R Brown, Susan O'Brien, Jacqueline C Barrientos, Neil E Kay, Fong Clow

N Engl J Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Jennifer A Woyach, Kelly Smucker, Lisa L Smith, Arletta Lozanski, Yiming Zhong, Fong Clow

Blood· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Susan O'Brien, Richard R Furman, Steven E Coutre, Jeff P Sharman, Jan A Burger, Fong Clow

Lancet Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Michael L Wang, Simon Rule, Peter Martin, Andre Goy, Rebecca Auer, Fong Clow

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
John C Byrd, Richard R Furman, Steven E Coutre, Ian W Flinn, Jan A Burger, Fong Clow

N Engl J Med· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
Tomasz M Beer, Christopher W Ryan, Peter M Venner, Daniel P Petrylak, Gurkamal S Chatta, Fong W Clow

J Clin Oncol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis